Ascendis Pharma A/S

NASDAQ•ASND

CEO: Mr. Jan Moller Mikkelsen

板块: Healthcare

行业: Biotechnology

上市日期: 2015-01-28

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.

联系方式

Tuborg Boulevard 12, Hellerup, 2900, Denmark

45-70-22-22-44

ascendispharma.com

市值

$14.84B

市盈率 (TTM)

-55.2

股息率

52周最高

$250.74

52周最低

$150.89

52周范围

91%

排名55Top 80.0%

2.6

F-Score

改良版 Piotroski 分析

基于 10 年期基本面

疲弱 • 2.6 / 9 分

评分区间 (0-9)

8-9: 价值优异

6-7: 基本面强劲

4-5: 整体稳健

0-3: 表现疲弱

数据范围: 2016-2025

财务仪表盘

Q4 2025 数据

营业收入

$285.45M+0.00%

近4季度走势

每股收益

-$0.63+0.00%

近4季度走势

自由现金流

$78.44M+0.00%

近4季度走势

2025 Annual 财报亮点

核心亮点

Revenue Surge Driven by YORVIPATH Total revenue €720.1M, up €356.5M; YORVIPATH sales €477.4M, up €448.7M compared to 2024.

Operating Loss Significantly Reduced Operating loss €136.3M, improvement €142.5M versus prior year's €278.8M loss reported for 2024.

Positive Operating Cash Flow Cash flow from operations €53.9M, a €360.1M improvement from prior period cash usage of €306.2M.

Pipeline Milestones Achieved Secured Novo Nordisk deal; TransCon CNP NDA priority review with FDA PDUFA goal February 28, 2026.

关注风险

Future Viability Concerns Significant future losses incurred, making future viability assessment difficult; total equity deficit €162.8M.

Financing Dependency Risk Failure to secure needed capital could force delay, limit, or cease commercialization activities and product development.

Product Success Uncertainty Substantial dependence on product candidates succeeding in clinical trials or receiving necessary regulatory approval.

Supply Chain Single Source Reliance on third-parties for manufacturing, including single-source suppliers, risks material adverse business impact.

前瞻展望

Vision 2030 Blockbuster Goal Pursue Vision 2030 goal: achieve >€5B revenue for key products via worldwide commercialization efforts.

Pipeline Expansion Focus Expand pipeline in Endocrinology Rare Disease and pursue TransCon opportunities in >€5B indications.

Global Commercialization Execution Execute integrated organization strategy across US, Europe Direct, and International Markets for product launches.

Technology Platform Leverage Maximize value creation by leveraging TransCon technology platform through strategic collaborations with market leaders.

同行对比

营业收入 (TTM)

BAX

$11.24B

+5.7%

BMRN

$3.22B

+12.9%

RPRX

$2.38B

+5.1%

毛利率 (最新季度)

RPRX

100.0%

+0.0pp

IONS

96.1%

-0.7pp

EXEL

95.6%

+0.1pp

关键指标

股票代码	市值	市盈率 (TTM)	净资产收益率 (TTM)	负债率
RVMD	$30.23B	-25.6	-63.1%	6.7%
MRNA	$21.43B	-7.5	-30.1%	15.5%
ROIV	$21.03B	-25.3	-18.3%	4.0%

长期趋势

近4季度

营业收入

净利润

经营现金流

4季度营收复合增长率

39.0%

高速增长

4季度净利润复合增长率

N/M

盈利状态转变

现金流稳定性

50%

现金流需要关注

深度研究

下次财报:2026年4月29日

每股收益:-

营业收入:-

财务数据

电话会议

财务报告

新闻

利润表

资产负债表

现金流量表

财务比率

变化率

利润表	过去12个月

无数据